Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

BACKGROUND: Current evidence suggests that patients with Luminal A early breast cancer can skip chemotherapy or extended endocrine therapy, but immunohistochemistry-based biomarker analysis for St Gallen subtyping may not be reproducible. We asked whether RT-qPCR can be used instead to address this...

Descripción completa

Detalles Bibliográficos
Autores principales: Laible, Mark, Hartmann, Kerstin, Gürtler, Claudia, Anzeneder, Tobias, Wirtz, Ralph, Weber, Stephan, Keller, Thomas, Sahin, Ugur, Rees, Martin, Ramaswamy, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631550/
https://www.ncbi.nlm.nih.gov/pubmed/31307414
http://dx.doi.org/10.1186/s12885-019-5890-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631550/
https://www.ncbi.nlm.nih.gov/pubmed/31307414
http://dx.doi.org/10.1186/s12885-019-5890-z

Ejemplares similares